Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 10/20 | 0.51 |
| ▸ | RAB9A | P51151 | 10/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.47 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3596374 | 0.98 | HTT (0.53) | HTTMAPTHPGDALDH1A1NPC1 | |
| SCHEMBL27293915 | 0.83 | MAPT (0.56) | HTTMAPTHPGDALDH1A1NPC1 | |
| SCHEMBL193423 | 0.81 | MAPT (0.59) | HTTMAPTHPGDALDH1A1NPC1 | |
| SCHEMBL6531550 | 0.81 | MAPT (0.54) | HTTMAPTHPGDALDH1A1NPC1 | |
| SCHEMBL30390410 | 0.81 | MAPT (0.59) | HTTMAPTHPGDALDH1A1NPC1 | |
| Lithium Ion SCHEMBL31133341 | 0.79 | MAPT (0.57) | HTTMAPTHPGDALDH1A1NPC1 | |
| SCHEMBL359560 | 0.79 | HPGD (0.53) | HTTMAPTHPGDALDH1A1NPC1 | |
| SCHEMBL31068028 | 0.79 | HPGD (0.53) | HTTMAPTHPGDALDH1A1NPC1 | |
| SCHEMBL28612277 | 0.79 | MAPT (0.57) | HTTMAPTHPGDALDH1A1NPC1 | |
| SCHEMBL30134133 | 0.79 | NPC1 (0.54) | HTTMAPTHPGDALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240300931-A1 | Composition and Methods for Treating Attention Deficit Disorders | LIPPA ARNOLD STAN (US) | 2024-09-12 | — | — | US | disclosed |
| US-20240100023-A1 | Compositions and Methods For Treating Spinal Cord Injuries | LIPPA ARNOLD S (US) | 2024-03-28 | — | — | US | disclosed |
| US-11851434-B2 | Substituted pyrazolo[1,5-A]pyrazine compounds as ret kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2023-12-26 | — | — | US | disclosed |
| US-20230373982-A1 | Compositions And Methods For Treating Attention Deficit Disorders | LIPPA ARNOLD STAN (US) | 2023-11-23 | — | — | US | disclosed |
| EP-3571203-B1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20230129330-A1 | Compositions And Methods For Treating Attention Deficit Disorders | LIPPA ARNOLD STAN (US) | 2023-04-27 | — | — | US | disclosed |
| CN-110267960-B | Substituted pyrazolo [1,5-a ] pyrazine compounds as RET kinase inhibitors | 阿雷生物药品公司 | 2022-04-26 | — | — | CN | disclosed |
| US-20220119396-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2022-04-21 | — | — | US | disclosed |
| US-11168090-B2 | Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2021-11-09 | — | — | US | disclosed |
| US-20210340130-A1 | Compositions and methods for treating attention deficit disorders | LIPPA ARNOLD STAN (US) | 2021-11-04 | — | — | US | disclosed |
| US-20030153556-A1 | Piperazine and homopiperazine compounds | MILLENNIUM PHARMACEUTICALS, INC. | 2003-08-14 | — | — | US | disclosed |
| US-20030149277-A1 | Triarylimidazole derivatives as cytokine inhibitors | SMITHKLINE BEECHAM CORPORATION | 2003-08-07 | — | — | US | disclosed |
| US-20030105142-A1 | Amide derivatives useful as inhibitors of the production of cytokines | ASTRAZENECA AB | 2003-06-05 | — | — | US | disclosed |
| WO-2003022214-A2 | PIPERAZINE AND HOMOPIPERAZINE COMPOUNDS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2003-03-20 | — | — | WO | disclosed |
| EP-1268465-A1 | TRIARYLIMIDAZOLE DERIVATIVES AS CYTOKINE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-01-02 | — | — | EP | disclosed |
| US-6432949-B1 | Amide derivatives useful as inhibitors of the production of cytokines | ASTRAZENECA AB (SE) | 2002-08-13 | — | — | US | disclosed |
| CN-1321150-A | Amide derivs. useful as inhibitors of production of cytokines | ASTRAZENECA AB (SE) | 2001-11-07 | — | — | CN | disclosed |
| WO-2001072737-A1 | TRIARYLIMIDAZOLE DERIVATIVES AS CYTOKINE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-10-04 | — | — | WO | disclosed |
| EP-1102750-A1 | AMIDE DERIVATIVES USEFUL AS INHIBITORS OF THE PRODUCTION OF CYTOKINES | AstraZeneca AB (SE) | 2001-05-30 | — | — | EP | disclosed |
| WO-2000007991-A1 | AMIDE DERIVATIVES USEFUL AS INHIBITORS OF THE PRODUCTION OF CYTOKINES | ASTRAZENECA AB (SE) | 2000-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210340130-A1 | Compositions and methods for treating attention deficit disorders | GRIN2A, GRIN2C, GRM2 | HTT 1227/4885MAPT 446/4885HPGD 1967/4885 |
| US-20240100023-A1 | Compositions and Methods For Treating Spinal Cord Injuries | CHAT, NTRK2, GMFG | HTT 2598/4885MAPT 433/4885HPGD 2429/4885 |
| US-20220119396-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, ROR1 | HTT 3810/4885MAPT 1938/4885HPGD 4052/4885 |
| US-20030153556-A1 | Piperazine and homopiperazine compounds | HAMP, MPL, F2 | HTT 65/4885MAPT 4002/4885HPGD 119/4885 |
| US-20230129330-A1 | Compositions And Methods For Treating Attention Deficit Disorders | GRIN2A, GRIN2C, GRM2 | HTT 1227/4885MAPT 446/4885HPGD 1967/4885 |
| US-11851434-B2 | Substituted pyrazolo[1,5-A]pyrazine compounds as ret kinase inhibitors | RET, BRAF, ROR1 | HTT 3810/4885MAPT 1938/4885HPGD 4052/4885 |
| US-20030105142-A1 | Amide derivatives useful as inhibitors of the production of cytokines | IL6, IL6ST, IL2 | HTT 2395/4885MAPT 4663/4885HPGD 725/4885 |
| US-11168090-B2 | Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors | RET, BRAF, ROR1 | HTT 3871/4885MAPT 1941/4885HPGD 4011/4885 |
| US-20230373982-A1 | Compositions And Methods For Treating Attention Deficit Disorders | GRIN2A, GRIN2C, GRM2 | HTT 1227/4885MAPT 446/4885HPGD 1967/4885 |
| US-20240300931-A1 | Composition and Methods for Treating Attention Deficit Disorders | GRIN2A, GRIN2C, NTRK2 | HTT 1037/4885MAPT 387/4885HPGD 2020/4885 |
| US-20030149277-A1 | Triarylimidazole derivatives as cytokine inhibitors | IL2, IL2RA, IL6ST | HTT 4201/4885MAPT 4189/4885HPGD 1036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.